# Immunovant Inc. (IMVT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $39.25, market value $8.1 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Immunovant Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 11.0×**. The shares trade at 11.0× book value; most of the value is in earnings power and intangibles rather than the balance sheet.

## Profitability
- **Return on equity: -59.3%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -1.5%**. Earnings per share fell 1.5%.

## Financial health
- **Current ratio: 9.09** (quick 9.09). Current assets cover the next year's liabilities 9.09 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Immunovant Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (16 analysts). 16 analysts cover Immunovant Inc.; the consensus is buy, with an average price target of $48.88 (+25% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 143.5%** (YTD 54.4%, 3-mo 26.2%). The shares are up 143.5% over twelve months including dividends.
- **From 52-week high: -13.6%** (169.2% above the low). Trading 14% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 39**. An RSI of 39 is neutral.
- **Beta (1 yr): 1.39** (volatility 60%). Beta of 1.39 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IMVT · Page: https://foliofundamentals.com/stocks/imvt

Not investment advice.